Quince Therapeutics, Inc. - Common Stock QNCX 深 沪
已收盘 09-19 16:00:00 美东时间
1.60
-0.010
-0.62%
华盛通- 最 高1.63
- 今 开1.60
- 成交量 34.97万股
- 最 低 1.58
- 昨 收 1.61
- 总市值 8594.21万
- 52周最高 2.45
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 0.69
- 委 比 -68.32%
- 总股本 5371.38万
- 历史最高 121.98
- 量 比 1.64
- 振 幅 3.11%
- 历史最低 0.5116
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JMP Securities Maintains Market Outperform on Quince Therapeutics, Lowers Price Target to $8
JMP Securities analyst Jonathan Wolleben maintains Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform and lowers the price target from $9 to $8.
08-12 21:12
Quince Therapeutics Q2 EPS $(0.34) Misses $(0.26) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 46.88 percent increase over losses of $(0.64) per share
08-12 04:19
JMP Securities Initiates Coverage On Quince Therapeutics with Market Outperform Rating, Announces Price Target of $9
JMP Securities analyst Jonathan Wolleben initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform rating and announces Price Target of $9.
08-05 20:40
Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial To Evaluate eDSP For Treatment Of Rare Neurodegenerative Disease Ataxia-Telangiectasia
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed
07-16 20:06
Quince Therapeutics Raises $11.5M in Private Placement
Quince Therapeutics ( ($QNCX) ) has shared an announcement. On June 12, 2025, Q...
06-14 05:46
Quince Therapeutics announces pricing of up to $22M private placement; shares up 22%
Quince Therapeutics (NASDAQ:QNCX) announces a private placement expected to generate $11.5M in upfront proceeds. The deal includes common stock (or pre-funded warrants) and accompanying common warrant...
06-13 05:31
美股大行评级 | 花旗首予霸王茶姬"买入"评级，CrowdStrike、达乐公司、Guidewire Software、Snowflake获多家机构上调评级和目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137304602125590529.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Wolfe Research：维持Cheche Group(CCG)"跑赢大市"评级，目标价从335美元升至350美元</p> <p>• HC Wainwright & Co.：上调AnaptysBio(ANAB)
06-05 09:42
Quince Therapeutics Says Pivotal Phase 3 NEAT Clinical Trial In Rare Neurodegenerative Disease A-T Reaches Important Milestone As Enrollment Now Exceeds 75%
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT
06-04 04:12
美股大行评级 | 潜在涨幅592.64%！Larimar Therapeutics获HC Wainwright升目标价至16美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111574370732224512.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Larimar Therapeutics(LRMR)"买入"评级，目标价从15美元升至16美元</p> <p>• HC Wainwright & Co.：维持Au
03-26 08:45
美股大行评级 | 潜在涨幅586.27%！HC Wainwright & Co.上调Enlivex Therapeutics目标价至7美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111211417521721345.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Enlivex Therapeutics(ENLV)"买入"评级，目标价从6美元升至7美元</p> <p>• Maxim Group：上调Nexalin Technolo
03-25 09:37
